• Who We Are
    • Management
    • Board of Directors
  • Our Focus
    • Dismutase Mimetics
    • Reducing Oral Mucositis
    • Aiming to Increase Efficacy of Radiation Therapy
  • Our Pipeline
    • Avasopasem (GC4419)
    • Rucosopasem (GC4711)
    • Clinical Trials
    • Key Publications
  • Investors
    • IR Home
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Shareholder Services
  • Contact Us

Clinical Trials

For additional details on ongoing clinical trials, please visit www.clinicaltrials.gov.

Avasopasem

 

  • ROMAN: A Phase 3 Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients with Head/Neck Cancer
  • EUSOM: Phase 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
  • AESOP: Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

 

Rucosopasem

 

  • GRECO-1: A Phase 1/2 Study of Rucosopasem in Combination with SBRT for NSCLC
  • GRECO-2: A Phase 2b Study of Rucosopasem in Combination with SBRT for Non-metastatic Pancreatic Cancer

 

© Copyright 2022 Galera Therapeutics, Inc.
GAL-032 December 2022
Website Design & Development Graphic Beans
Privacy Policy – Terms of Use – Compassionate Use Policy

LinkedIn Twitter icon

Group Chart